Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-55~* Physically healthy and not currently pregnant~* Primary diagnosis of OCD~* Sufficient severity of symptoms~* For all patients on medications, medications dose must be stable for at least 6 weeks prior to enrollment. Must discuss with Dr. current medications and doses.~* Able to provide consent~Exclusion Criteria:~* First degree relative with schizophrenia~* Psychiatric conditions that would make participation unsafe determined by study doctor~* Female patients who are either pregnant or nursing~* Planning to start EX/RP during the period of the study or those who have completed an adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment.~* Nasal obstruction or history of nasal surgery~* Currently on psychotropic medication or other medication likely to interact with the glutamate system~* Medical conditions that make participation unsafe~* Allergy or intolerance to ketamine or midazolam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: PLACEBO_COMPARATOR): A single dose of intranasal midazolam up to 4 mg
- Ketamine (Type: EXPERIMENTAL): A single dose of intranasal ketamine up to 50 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).